微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 22.15% | 8.63% | -8.62% | 135/157 | 48.88% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 24.24% | 35.08% | 15.9% | 127/157 | 50.55% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 20.91% | -7.42% | 1.67% | 133/157 | 50.61% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 20.57% | -13.96% | 0.87% | 132/157 | -2.2% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 20.39% | -12.43% | 13.64% | 132/157 | 14.82% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 17.94% | -17.06% | -20.57% | 133/157 | 31.96% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 22.59% | -8.92% | -5.51% | 132/157 | 51.88% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 23.91% | 10.63% | 2.67% | 129/157 | 22.51% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 23.29% | 26.45% | 7.63% | 134/157 | 33.12% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 21.63% | 73.26% | -12.77% | 134/157 | 51.76% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 24.8% | -13.49% | 14.77% | 130/157 | 51.61% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 21.61% | -13.04% | 17.35% | 134/157 | 32.47% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 18.41% | -25.7% | 47.48% | 137/157 | 38.42% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 12.49% | -49.64% | -56.44% | 137/157 | 52.97% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 28.67% | -22.31% | 15.36% | 121/157 | 53.83% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 24.85% | -20.62% | 0.27% | 125/157 | 5.64% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 24.78% | -10.44% | -0.05% | 132/157 | 20.99% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 24.8% | 9.72% | -32.81% | 123/157 | 54.39% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 36.9% | 3.38% | 17.87% | 115/157 | 55.2% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 31.31% | -13.27% | 13.13% | 107/157 | 46.77% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 27.67% | -14.12% | 22.45% | 126/157 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 22.6% | -11.56% | -36.69% | 116/157 | 54.13% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 35.7% | 111.74% | -1.11% | 114/157 | -148.64% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 36.1% | 101.44% | 12.02% | 97/157 | 56.43% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 32.22% | 68.36% | 26.1% | 112/157 | 54.17% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 25.55% | 55.43% | 51.58% | 99/157 | 55.17% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 16.86% | 154.11% | -5.92% | 130/157 | -1242.15% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 17.92% | 121.12% | -6.38% | 102/157 | 55.23% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 19.14% | 81.19% | 16.42% | 109/157 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 16.44% | 260.96% | 147.82% | 101/157 | 51.07% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 6.63% | -44.73% | -18.14% | 127/157 | -211.97% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 8.1% | -40.95% | -23.28% | 97/157 | 54.14% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 10.56% | -13.84% | 131.92% | 101/157 | 53.53% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 4.55% | -49.16% | -62.05% | 96/157 | 54.16% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 12% | -44.93% | -12.54% | 117/157 | 52.55% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 13.72% | -38.69% | 11.94% | 93/157 | 49.09% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 12.26% | -47.9% | 36.86% | 99/157 | 47.91% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 8.96% | -39.45% | -58.89% | 85/157 | 46.94% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 21.79% | -2.71% | -2.64% | 104/157 | 48.46% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 22.38% | 5.35% | -4.89% | 75/157 | 46.19% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 23.53% | 19.31% | 59.07% | 80/157 | 46.26% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 14.8% | -13.55% | -33.95% | 77/157 | 43.86% | 贝达药业 | 97.01% | 行业排名> |